Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5205216
Max Phase: Preclinical
Molecular Formula: C28H44N6O3S2
Molecular Weight: 576.83
Associated Items:
ID: ALA5205216
Max Phase: Preclinical
Molecular Formula: C28H44N6O3S2
Molecular Weight: 576.83
Associated Items:
Canonical SMILES: Cc1ccc([C@H](CCN2[C@@H]3CC[C@H]2C[C@H](n2c(C)nnc2C(C)C)C3)NC(=O)C2CCN(S(C)(=O)=O)CC2)s1
Standard InChI: InChI=1S/C28H44N6O3S2/c1-18(2)27-31-30-20(4)34(27)24-16-22-7-8-23(17-24)33(22)15-12-25(26-9-6-19(3)38-26)29-28(35)21-10-13-32(14-11-21)39(5,36)37/h6,9,18,21-25H,7-8,10-17H2,1-5H3,(H,29,35)/t22-,23+,24-,25-/m0/s1
Standard InChI Key: DNEBYUITDMGYTI-NDBXHCKUSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 576.83 | Molecular Weight (Monoisotopic): 576.2916 | AlogP: 4.17 | #Rotatable Bonds: 9 |
Polar Surface Area: 100.43 | Molecular Species: BASE | HBA: 8 | HBD: 1 |
#RO5 Violations: 1 | HBA (Lipinski): 9 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 13.29 | CX Basic pKa: 9.12 | CX LogP: 1.79 | CX LogD: 0.07 |
Aromatic Rings: 2 | Heavy Atoms: 39 | QED Weighted: 0.48 | Np Likeness Score: -1.57 |
1. Xie X, Zheng YG, Chen H, Li J, Luo RH, Chen L, Zheng CB, Zhang S, Peng P, Ma D, Yang LM, Zheng YT, Liu H, Wang J.. (2022) Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability., 65 (24.0): [PMID:36472561] [10.1021/acs.jmedchem.2c01383] |
Source(1):